Abstract 607P
Background
Melanoma brain metastasis has very poor prognosis, although recent treatment advances, including immune checkpoint inhibitors and targeted therapy, have improved the prognosis. We investigated the survival of Asian patients with melanoma brain metastasis and the effectiveness of radiotherapy and systemic therapies.
Methods
We retrospectively reviewed the survival rates of patients diagnosed with melanoma brain metastasis between January 2011 and December 2021 at the National Cancer Center Hospital in Tokyo, Japan. In addition, we identified factors associated with survival using Cox regression analysis.
Results
A total of 135 patients were included. The median overall survival after melanoma brain metastasis diagnosis was 7.8 months (95% confidence interval [CI] 6.1–9.6). The 6-month and 1-year survival rates were 60.7% and 34.8%, respectively. We identified the prognostic factors of melanoma brain metastasis, including non-acral primary location, low serum LDH levels, systemic therapy of single-agent immune check point inhibitors or targeted therapies, and radiotherapy of stereotactic irradiation. On the other hand, We found no significant difference in effectiveness between single-agent immune check point inhibitors, the combination of immune check point inhibitors, and targeted therapies.
Conclusions
We retrospectively investigated the survival of patients with melanoma brain metastasis at our facility. The survival of Asian patients with melanoma brain metastasis is relatively poor compared to that of Caucasian patients. Immune check point inhibitor, targeted therapy, and radiotherapy of stereotactic irradiation were associated with improved survival; however, we found no significant superiority of the combination of immune check point inhibitors over single-agent immune check point inhibitor or targeted therapy in terms of effectiveness. Further investigations using larger cohorts, multicenter analyses, and prospective studies are necessary to assess the effectiveness of systemic therapy in Asian patients with melanoma brain metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dermatologic oncology department in National Cancer Center Hospital.
Funding
Has not received any funding.
Disclosure
N. Yamazaki: Financial Interests, Personal, Advisory Board: Ono, Chugai; Financial Interests, Personal, Invited Speaker: Ono, Bristol Myers Squibb, Novartis, MSD, Maruho; Financial Interests, Institutional, Research Grant: Ono, Bristol Myers Squibb, Novartis, Amgen. K. Namikawa: Financial Interests, Personal, Advisory Board: MSD, Novartis; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers Squibb, Novartis, MSD, Ono. All other authors have declared no conflicts of interest.
Resources from the same session
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract